Intra-Cellular Therapies reports completion of enrollment of ITI-007-302 phase 3 trial
Intra-Cellular Therapies announced completion of enrollment in the second Phase 3 clinical trial (ITI-007-302) of the Company's lead product candidate ITI-007 for the treatment of schizophrenia. The Company anticipates topline data will be available later this year. June 30, 2016